Dopaminergic and noradrenergic dynamics after acute stress

Recruiting

• Conditions: Anxiety disorders; Stress-related disorders; 10002861

• Registration Number: NL-OMON51949
• Lead Sponsor: Radboud Universitair Medisch Centrum

Brief Summary

Not available

Detailed Description

Not available

Study Timeline

• Last Update Posted: 18 June 2024

Recruitment & Eligibility

• Status: Recruiting
• Sex: Not specified
• Target Recruitment: 132

Inclusion Criteria

Age between 18 and 40
Right handed
BMI between 18.5 and 30
Normal or corrected to normal vision
Speaking and understanding of the English language

Exclusion Criteria

Incompatibility with the MRI scanner
History of brain surgery
Possible pregnancy
Breastfeeding
Color blindness
Any relevant current or past psychiatric or psychotic disorder, including
suicidality
First degree family member with schizophrenia, bipolar disorder, or major
depressive disorder
Neurological disorder
Endocrine disorder
Endocrine treatment
Glaucoma or increased risk for glaucoma
Melanoma or undiagnosed skin lesion
Any other clinically significant hepatic, metabolic, obstructive respiratory,
renal, cerebrovascular, cardiovascular, oncological, ocular or pulmonary
disease/disorders
Raynaud*s syndrome
Hypersensitivity to Haloperidol or Propranolol
Hypertension (i.e. diastolic blood pressure >95 mmHg at rest, or systolic blood
pressure >180
mmHg at rest)
Hypotension (i.e. diastolic blood pressure <50 mmHg at rest, or systolic blood
pressure <95
mmHg at rest, or heart rate <45 bpm)
A-V block (PR interval longer than 0.20sec or irregular PR intervals)
Abnormal QTc-interval (higher than 450 for males, and 460 for females)
Frequent autonomic failure (fainting, dizziness, blurry vision)

Used prescribed medication within the last month
Use of *over the counter* medication within the last two months (excluding
paracetamol)
Dependence on alcohol or drugs
Use of alcohol within 24 hours before the test sessions
Average alcohol consumption of 3 beverages or more daily
Use of drugs within 72 hours before the test sessions
Cannabis use within 2 weeks prior to start of the study, weekly use for a
duration of at least 3
months in the last 6 months
Weekly or more use of recreational drugs or psychotropic medication
Habitual smoking (more than one pack in a week) or inability to cease smoking
for 24 hours
before testing
Irregular sleep/wake rhythm
Intense daily physical exercise
Native English speaker

Study & Design

• Study Type: Interventional
• Study Design: Not specified

Primary Outcome Measures

Name	Time	Method
<p>The main study parameters are the comparison of oddball performance and<br /><br>performance in the cue-guided versus memory-guided attention task, between the<br /><br>stress and placebo group, the stress and haloperidol group, and the stress and<br /><br>propranolol group.</p><br>

Secondary Outcome Measures

Name	Time	Method
<p>In this study, three secondary outcome parameters are measured. First, the<br /><br>difference in vigilance and striatal-dependent cognition between the group<br /><br>receiving Propranolol and the group receiving Haloperidol is investigated.<br /><br>Second, the difference in neural activity between the different groups is<br /><br>assessed during the oddball and visual search task.<br /><br>Third, the difference in behavioral measures and neural activity in the<br /><br>different groups is measured during a motivation task, a working memory task,<br /><br>and an emotion task.</p><br>